|
Session 23
Oral Abstracts
HIV Vaccines
Tuesday, 10-11:30 am
Room: Auditorium |
| 10:00 am 85 |
GeoVax Clade B DNA/MVA HIV/AIDS Vaccine Is Well Tolerated and Immunogenic when Administered to Healthy Seronegative Adults (HVTN 065 part A)
Harriet Robinson*1, P Goepfert2, C Hay3, S Frey4, W Blattner5, P Wright6, M Elizaga7, L Qin7, B Moss8, and HVTN 065 Protocal Team
1GeoVax Inc, Atlanta, GA, US; 2Univ of Alabama at Birmingham, US; 3Univ of Rochester, NY, US; 4St Louis Univ, MO, US; 5Inst of Human Virology, Univ of Maryland, Baltimore, US; 6Vanderbilt Univ, Nashville, TN, US; 7Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; and 8NIAID, NIH, Bethesda, MD, US |
| 10:15 am 86 |
Cellular Immune Responses in HIV-1 Uninfected Adult Tanzanian Volunteers Enrolled in a Phase I/II Multiclade HIV-1 DNA Plasmid Vaccine (VRC-HIVDNA016-00-VP)/Adenovirus-5 Vector(VRC-HIVADV014-00-VP) Boost Vaccine Trial
Alexandra Schuetz*1,2, A Haule1, M Schunk1, L Maboko1, M Hoelscher1, M Robb2, N Michael2, B Graham3, J Cox2, and M de Souza2,4
1Mbeya Med Res Prgm, Tanzania; 2US Military HIV Res Prgm, Rockville, MD, US; 3Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US; and 4Armed Forces Res Inst of Med Sci, Bangkok, Thailand |
| 10:30 am 87 |
Therapeutic Vaccination with a Replication Defective Adenovirus Type 5 HIV-1 gag Vaccine in a Prospective, Double-blinded, Placebo-controlled Trial (ACTG 5197)
Robert Schooley*1, H Wang2, J Spritzler2, M Lederman3, D Havlir4, D Kuritzkes5, C Battaglia6, C Godfrey7, M Robertson8, B Schock9, and AIDS Clinical Trials Group
1Univ of California, San Diego, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Case Western Reserve Univ, Cleveland, OH, US; 4Univ of California, San Francisco, US; 5Partners Hlthcare, Boston, MA, US; 6Social & Sci Systems, Silver Spring, MD, US; 7Div of AIDS, NIAID, NIH, Bethesda, MD, US; 8Merck Res Labs, North Wales, PA, US; and 9Frontier Sci and Tech Res Fndn, Amherst, NY, US |
| 10:45 am 88LB |
Efficacy Results from the STEP Study (Merck V520 Protocol 023/HVTN 502): A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine
M Robertson1, D Mehrotra1, D Fitzgerald2, A Duerr3, D Casimiro1, J McElrath3, D Lawrence4, and Susan Buchbinder*5
1Merck Res Labs, West Point, PA, US; 2GHESKIO, Port-au-Prince, Haiti; 3HIV Vaccine Trials Network, Seattle, WA, US; 4NIAID, NIH, Bethesda, MD, US; and 5San Francisco Dept of Publ Hlth, CA, US |
| 11:05 am 89LB |
Immunological Characterization of Subjects from the STEP Study: A Phase IIB Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine
Michael Robertson*1, D Casimiro1, S De Rosa2, S Dubey1, L Kierstead1, and J McElrath2
1Merck Res Labs, West Point, PA, US and 2Fred Hutchinson Cancer Res Ctr, HIV Vaccine Trials Network, Seattle, WA, US |
|
